KRRO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Korro Bio Inc (KRRO) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is supported by strong analyst upgrades, a clear focus on addressing unmet medical needs, and significant hedge fund buying. Despite some financial challenges, the company's pivot to promising RNA editing technology and upcoming catalysts make it a compelling long-term investment.
The MACD is positive at 0.123, indicating a bullish trend, though it is contracting. RSI is neutral at 56.616, and moving averages are converging, suggesting consolidation. The stock is trading near its pivot level of 13.722, with key resistance at 15.064 and support at 12.379.
Strong analyst upgrades with price targets ranging from $15 to $30, reflecting confidence in the KRRO-121 program.
Hedge fund buying has surged by 1445.31% over the last quarter.
Upcoming presentations at major conferences, including the International Conference on Ureagenesis Defects and the American Society of Gene and Cell Therapy Annual Meeting, which could further validate the company's technology.
Financial performance shows a revenue drop of -43.11% YoY in Q4 2025, though net income and EPS have improved.
No recent congress trading data or significant insider activity, which could indicate limited institutional confidence.
In Q4 2025, revenue dropped by -43.11% YoY to $1,292,000. However, net income improved to -$50,042,000 (up 136.06% YoY), and EPS increased to -5.32 (up 135.40% YoY). Gross margin remained steady at 100%. While revenue decline is concerning, the improvement in net income and EPS reflects better cost management.
Analysts are overwhelmingly bullish on KRRO, with multiple upgrades to Buy or Outperform and price targets ranging from $15 to $30. The focus on KRRO-121 for hyperammonemia and hepatic encephalopathy is seen as a strong growth driver, with significant upside potential.
